$Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab$

Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab

Wierda, William; Kipps, Thomas; Mayer, Jiří; Stilgenbauer, Stephan; Williams, Cathy D.; Hellmann, Andrzej; Robak, Tadeusz; Furman, Richard R.; Hillmen, Peter; Trneny, Marek; Dyer, Martin J.S.; Padmanabhan, Swami; Piotrowska, Magdalena; Kozak, Tomas; Chan, Geoffrey; Davis, Randy; Losic, Nedjad; Wilms, Joris; Russell, Charlotte; Österborg, Anders

期刊名称Clinical Lymphoma and Myeloma
作者Wierda, William; Kipps, Thomas; Mayer, Jiří; Stilgenbauer, Stephan; Williams, Cathy D.; Hellmann, Andrzej; Robak, Tadeusz; Furman, Richard R.; Hillmen, Peter; Trneny, Marek; Dyer, Martin J.S.; Padmanabhan, Swami; Piotrowska, Magdalena; Kozak, Tomas; Chan, Geoffrey; Davis, Randy; Losic, Nedjad; Wilms, Joris; Russell, Charlotte; Österborg, Anders
卷第9卷
期第6期
印刷ISSN1557-9190
文件大小52.74KB
发表时间2009-12
DOI10.3816/clm.2009.n.098

发现好书期刊，享受阅读乐趣

Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab